Overview of India’s Precision Medicine Drive Union Minister of State (Independent Charge) for Science & Technology, Dr. Jitendra Singh , addressed the NXT Summit 2026, declaring that India is moving into a transformative era of personalised and precision medicine . The thrust is powered by genomics , AI and advanced biotechnology. Key Developments India’s vast genetic diversity (4,000‑5,000 distinct communities) provides a unique platform for large‑scale genomic research. The Genome India project has sequenced 10,000 genomes; the target is one million to strengthen preventive healthcare. Launch of the Bio‑E3 Policy to accelerate biomanufacturing, positioning India among the top global players. Successful gene‑therapy trials for haemophilia and development of DNA‑based COVID‑19 vaccine and indigenous HPV vaccine. AI‑enabled early‑detection programmes, especially for breast cancer, using thermal imaging in mobile health units. Collaboration between the Department of Space and AIIMS on space‑medicine research. Introduction of the SHANTI Act to invite private investment in nuclear technologies and medicine. Creation of a ₹1 lakh crore RDI Fund for biotech, nuclear science and emerging healthcare solutions. Important Facts India now ranks third in the Asia‑Pacific region for bio‑manufacturing, supported by bio‑foundries, clusters and Bio‑NEST incubators. The government’s push has made India a cost‑effective, high‑quality healthcare destination, attracting global collaborations through platforms like the Parliamentarians’ Forum on Life Sciences. UPSC Relevance These developments intersect with several GS papers: GS3 – Science & Technology (genomics, AI, biotechnology, nuclear energy), GS1 – Indian Heritage & Culture (India’s genetic diversity), and GS4 – Ethics (ethical aspects of gene therapy and AI in healthcare). Understanding the policy framework (Bio‑E3, SHANTI Act, RDI Fund) is essential for questions on health sector reforms, innovation ecosystems and India’s global positioning. Way Forward Scale up genome sequencing to the million‑genome target, ensuring robust data privacy and ethical oversight. Strengthen public‑private partnerships under the RDI Fund to commercialise biotech breakthroughs. Expand AI‑driven diagnostic networks to remote areas, integrating them with existing primary health centres. Monitor gene‑therapy outcomes and establish regulatory guidelines to address safety and accessibility. Leverage space‑medicine research for innovations in tele‑health and remote monitoring. Collectively, these steps aim to cement India’s leadership in the next industrial revolution driven by biotechnology and precision healthcare.